Icon (ICLR) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Icon (NASDAQ:ICLR) released its quarterly earnings data on Thursday. The medical research company reported $1.43 EPS for the quarter, beating the consensus estimate of $1.41 by $0.02, Morningstar.com reports. Icon had a return on equity of 28.60% and a net margin of 16.01%. The company had revenue of $455.10 million for the quarter, compared to analysts’ expectations of $455.66 million. During the same period last year, the firm posted $1.33 earnings per share. Icon’s revenue was up 4.6% compared to the same quarter last year. Icon updated its FY18 guidance to $5.89-6.09 EPS.

Icon (ICLR) opened at $115.01 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.90 and a quick ratio of 1.90. Icon has a 12 month low of $76.46 and a 12 month high of $124.48. The company has a market capitalization of $6,165.75, a PE ratio of 22.42, a PEG ratio of 1.60 and a beta of 0.48.

Hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC bought a new position in shares of Icon in the third quarter worth about $148,000. Financial Gravity Companies Inc. bought a new position in shares of Icon in the fourth quarter worth about $144,000. C M Bidwell & Associates Ltd. bought a new position in shares of Icon in the fourth quarter worth about $196,000. Advisor Partners LLC bought a new position in shares of Icon in the fourth quarter worth about $201,000. Finally, Dean Capital Investments Management LLC bought a new position in shares of Icon in the fourth quarter worth about $203,000. 89.66% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have issued reports on the company. SunTrust Banks reissued a “buy” rating and issued a $133.00 target price on shares of Icon in a research report on Monday, January 22nd. Zacks Investment Research raised Icon from a “hold” rating to a “buy” rating and set a $132.00 target price on the stock in a research report on Tuesday, January 9th. KeyCorp reissued a “buy” rating and issued a $130.00 target price on shares of Icon in a research report on Thursday, January 11th. ValuEngine raised Icon from a “hold” rating to a “buy” rating in a research report on Sunday, December 31st. Finally, Credit Suisse Group raised Icon to a “buy” rating and set a $131.00 target price on the stock in a research report on Friday. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Icon has a consensus rating of “Buy” and a consensus price target of $126.00.

COPYRIGHT VIOLATION WARNING: This report was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://stocknewstimes.com/2018/02/17/icon-iclr-releases-quarterly-earnings-results-beats-expectations-by-0-02-eps.html.

About Icon

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Earnings History for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply